Similar demographic and clinical features at study entry were observed between responders or non-responders RA to CTLA4-Ig treatment in terms of DAS remission (Supplemental Table 1), also stratifying RA patients for disease duration (data not shown). Here, CTLA4 is linked to rheumatoid arthritis.